New combo aims to stop liver cancer from coming back after surgery
NCT ID NCT06467799
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 35 times
Summary
This phase II trial tests whether giving chemotherapy directly into the liver artery plus an immunotherapy drug (tislelizumab) before surgery, followed by more immunotherapy after surgery, can prevent liver cancer from returning in high-risk patients. The study enrolls 39 adults with hepatocellular carcinoma beyond Milan criteria. The main goal is to see how many patients remain cancer-free one year after surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact Phone: •••-•••-••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tislelizumab (an immunotherapy drug) and FOLFOX chemotherapy given directly into the liver artery
What this could lead to
If successful, this approach could reduce the chance of liver cancer returning after surgery, potentially improving long-term survival for high-risk patients.
What could go wrong
This is a small, early-phase trial with only 39 participants and no comparison group, so results may not apply broadly. The combination therapy also carries risks of side effects from both chemotherapy and immunotherapy.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.